Adoption of MRI-guided Prostate Cancer Diagnostics and Surgical Outcomes: A Prospective Multicenter Registry Study.

Background Adoption of magnetic resonance imaging (MRI)-guided prostate biopsy across different health care settings remains variable, and its implementation, following guideline endorsement, has not been fully characterized, particularly with respect to temporal trends and downstream surgical outcomes.Design Setting And Participants We analyzed biopsy techniques and postoperative outcomes among men undergoing radical prostatectomy (2020-2025), using the prospective national SWISS urology prostatectomy registry.Outcome Measurements And Statistical Analysis Temporal trends in MRI-guided versus non-MRI-guided biopsy were compared across university, regional, and local/private hospitals. Multivariable logistic regression models were used to evaluate associations between biopsy technique and pathological and perioperative outcomes.Results And Limitations A total of 7687 men from 29 centers were included. A rapid transition from non-MRI-guided to MRI-guided biopsy was observed over the study period. University hospitals were early adopters of MRI-guided biopsy, with use approaching 85% by 2020 and achieving complete adoption by 2024. Regional and local/private hospitals showed a more gradual increase, with MRI-guided biopsy rising from 44% in 2020 to 88% by early 2025. In multivariable analyses, MRI-guided biopsy was associated with lower risk of understaging (odds ratio [OR] 0.64; 95% confidence interval [CI] 0.57-0.72; p < 0.001) and positive surgical margins (OR 0.80; 95% CI 0.70-0.92; p = 0.001), and was not associated with increased perioperative complications or International Society of Urological Pathology grade upgrading. Limitations include residual confounding and the selection of surgically treated patients.Conclusions MRI-guided biopsy rapidly became the dominant diagnostic approach, with academic centers leading adoption and other care settings converging thereafter, highlighting the important role of academic centers in implementing guideline-recommended diagnostics.

Authors

Institutions

Publication Details

Journal
Open Access CRIS of the University of Bern
Published
2026-07-24
DOI
https://doi.org/10.48620/99771
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adoption of MRI-guided Prostate Cancer Diagnostics and Surgical Outcomes: A Prospective Multicenter Registry Study.

Raphael Röthlisberger, Dominik Abt, Daniel P. Nguyen, Nicola Giudici et al.
Open Access CRIS of the University of Bern
Prostate Cancer Diagnosis and Treatment
article

Adoption of MRI-guided Prostate Cancer Diagnostics and Surgical Outcomes: A Prospective Multicenter Registry Study.

Raphael Röthlisberger, Dominik Abt, Daniel P. Nguyen, Nicola Giudici, Angelos Tasios, George Thalmann, Nicolas Arnold, Räto Strebel, Stephen Wyler, Laila Schneidewind, Agostino Mattei, Beat Roth
article en

Abstract

Background Adoption of magnetic resonance imaging (MRI)-guided prostate biopsy across different health care settings remains variable, and its implementation, following guideline endorsement, has not been fully characterized, particularly with respect to temporal trends and downstream surgical outcomes.Design Setting And Participants We analyzed biopsy techniques and postoperative outcomes among men undergoing radical prostatectomy (2020-2025), using the prospective national SWISS urology prostatectomy registry.Outcome Measurements And Statistical Analysis Temporal trends in MRI-guided versus non-MRI-guided biopsy were compared across university, regional, and local/private hospitals. Multivariable logistic regression models were used to evaluate associations between biopsy technique and pathological and perioperative outcomes.Results And Limitations A total of 7687 men from 29 centers were included. A rapid transition from non-MRI-guided to MRI-guided biopsy was observed over the study period. University hospitals were early adopters of MRI-guided biopsy, with use approaching 85% by 2020 and achieving complete adoption by 2024. Regional and local/private hospitals showed a more gradual increase, with MRI-guided biopsy rising from 44% in 2020 to 88% by early 2025. In multivariable analyses, MRI-guided biopsy was associated with lower risk of understaging (odds ratio [OR] 0.64; 95% confidence interval [CI] 0.57-0.72; p < 0.001) and positive surgical margins (OR 0.80; 95% CI 0.70-0.92; p = 0.001), and was not associated with increased perioperative complications or International Society of Urological Pathology grade upgrading. Limitations include residual confounding and the selection of surgically treated patients.Conclusions MRI-guided biopsy rapidly became the dominant diagnostic approach, with academic centers leading adoption and other care settings converging thereafter, highlighting the important role of academic centers in implementing guideline-recommended diagnostics.

Open Access CRIS of the University of Bern
Fincantieri (Italy) (IT)
Partnerships for the goals
Openalex Percentile: Top 9%
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.